Loading...
Nabriva Therapeutics plc
NBRV•NASDAQ
Healthcare
Biotechnology
$1.42
$0.01(0.71%)
Nabriva Therapeutics plc (NBRV) AI-Powered Stock Analysis
See how Nabriva Therapeutics plc scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerNabriva Therapeutics plc (NBRV) Stock Overall Grade
Nabriva Therapeutics plc’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to Nabriva Therapeutics plc's overall stock rating.
Forecast
C+Score
56/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
CScore
45/100Sector Comparison
B+Score
75/100Industry Comparison
B+Score
75/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
50/100Nabriva Therapeutics plc (NBRV) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 56/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (45/100, C) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Nabriva Therapeutics plc stock grade, including financials, comparisons, and forecasts.